Thus, systemic acidosis or the other side effects associated with oral carbonicanhydraseinhibitors are not expected to occur.
因此，不会出现全身酸中毒或其他与口服碳酸酐酶抑制剂有关的副作用。
2
Carbonicanhydraseinhibitors (CAIs) were first used to lower intraocular pressure (IOP) in glaucoma in 1954, with the introduction of acetazolamide, methazolamide and diclofenamide were subsequently.